JP2025166121A5 - - Google Patents
Info
- Publication number
- JP2025166121A5 JP2025166121A5 JP2025133450A JP2025133450A JP2025166121A5 JP 2025166121 A5 JP2025166121 A5 JP 2025166121A5 JP 2025133450 A JP2025133450 A JP 2025133450A JP 2025133450 A JP2025133450 A JP 2025133450A JP 2025166121 A5 JP2025166121 A5 JP 2025166121A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- patient
- treatment
- product according
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950828P | 2019-12-19 | 2019-12-19 | |
| US62/950,828 | 2019-12-19 | ||
| PCT/US2020/066224 WO2021127572A1 (en) | 2019-12-19 | 2020-12-18 | Methods of schizophrenia treatment |
| JP2022537550A JP7727634B2 (ja) | 2019-12-19 | 2020-12-18 | 統合失調症処置方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537550A Division JP7727634B2 (ja) | 2019-12-19 | 2020-12-18 | 統合失調症処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025166121A JP2025166121A (ja) | 2025-11-05 |
| JP2025166121A5 true JP2025166121A5 (enExample) | 2026-04-27 |
Family
ID=76437353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537550A Active JP7727634B2 (ja) | 2019-12-19 | 2020-12-18 | 統合失調症処置方法 |
| JP2025133450A Pending JP2025166121A (ja) | 2019-12-19 | 2025-08-08 | 統合失調症処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537550A Active JP7727634B2 (ja) | 2019-12-19 | 2020-12-18 | 統合失調症処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210186962A1 (enExample) |
| EP (2) | EP4744678A3 (enExample) |
| JP (2) | JP7727634B2 (enExample) |
| DK (1) | DK4076461T3 (enExample) |
| ES (1) | ES3067760T3 (enExample) |
| FI (1) | FI4076461T3 (enExample) |
| HR (1) | HRP20260406T1 (enExample) |
| LT (1) | LT4076461T (enExample) |
| PL (1) | PL4076461T3 (enExample) |
| PT (1) | PT4076461T (enExample) |
| RS (1) | RS67890B1 (enExample) |
| SI (1) | SI4076461T1 (enExample) |
| SM (1) | SMT202600134T1 (enExample) |
| WO (1) | WO2021127572A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428506B2 (en) | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| SMT202600133T1 (it) | 2018-03-23 | 2026-05-12 | Intra Cellular Therapies Inc | Composti organici |
| AU2019328528B2 (en) | 2018-08-31 | 2025-01-23 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| IL297333B2 (en) * | 2020-04-17 | 2025-09-01 | Honeybrains Llc | Preparations and methods for treating neuropsychiatric disorders |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000077001A1 (en) | 1999-06-15 | 2000-12-21 | Du Pont Pharmaceuticals Company | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| MX394214B (es) | 2007-03-12 | 2025-03-24 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo substituido. |
| CA2719824A1 (en) * | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| ES2530090T3 (es) | 2008-03-12 | 2015-02-26 | Intra-Cellular Therapies, Inc. | Sólido de gamma-carbolinas fusionadas con heterociclo sustituido |
| CA2725342C (en) | 2008-05-27 | 2024-02-20 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders |
| KR102967223B1 (ko) * | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| KR20220054908A (ko) | 2014-04-04 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP7013454B2 (ja) * | 2016-10-12 | 2022-02-15 | イントラ－セルラー・セラピーズ・インコーポレイテッド | アモルファス固体分散体 |
| CA3082834A1 (en) * | 2017-11-22 | 2019-05-31 | Concert Pharmaceuticals, Inc. | Deuterated analogs of d-serine and uses thereof |
| WO2019102240A1 (en) * | 2017-11-27 | 2019-05-31 | Egis Gyógyszergyár Zrt. | Method for the manufacture of lumateperone and its salts |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020047408A1 (en) * | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020112941A2 (en) * | 2018-11-27 | 2020-06-04 | Teva Czech Industries S.R.O | Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof |
-
2020
- 2020-12-18 LT LTEPPCT/US2020/066224T patent/LT4076461T/lt unknown
- 2020-12-18 EP EP26153433.3A patent/EP4744678A3/en active Pending
- 2020-12-18 SM SM20260134T patent/SMT202600134T1/it unknown
- 2020-12-18 US US17/127,867 patent/US20210186962A1/en active Pending
- 2020-12-18 DK DK20900863.0T patent/DK4076461T3/da active
- 2020-12-18 EP EP20900863.0A patent/EP4076461B1/en active Active
- 2020-12-18 PL PL20900863.0T patent/PL4076461T3/pl unknown
- 2020-12-18 SI SI202030742T patent/SI4076461T1/sl unknown
- 2020-12-18 WO PCT/US2020/066224 patent/WO2021127572A1/en not_active Ceased
- 2020-12-18 ES ES20900863T patent/ES3067760T3/es active Active
- 2020-12-18 RS RS20260344A patent/RS67890B1/sr unknown
- 2020-12-18 PT PT209008630T patent/PT4076461T/pt unknown
- 2020-12-18 FI FIEP20900863.0T patent/FI4076461T3/fi active
- 2020-12-18 HR HRP20260406TT patent/HRP20260406T1/hr unknown
- 2020-12-18 JP JP2022537550A patent/JP7727634B2/ja active Active
-
2025
- 2025-08-08 JP JP2025133450A patent/JP2025166121A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101607081B1 (ko) | 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약 | |
| US8633230B2 (en) | Viral hepatitis treatment | |
| JP2023507584A5 (enExample) | ||
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| JP2019515884A (ja) | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 | |
| JP2015522080A (ja) | スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物 | |
| WO2019006050A1 (en) | NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN TREATING DEPRESSION | |
| JP2026016527A5 (enExample) | ||
| EP3931178A1 (en) | Compounds for prevention and treatment of post-operative cognitive dysfunction | |
| JP2009514793A (ja) | 医薬剤の胃腸吸収を増大するための製剤および方法 | |
| US20220168307A1 (en) | Treatment of sma | |
| JP5026255B2 (ja) | 感染症の治療 | |
| CN1859913A (zh) | 改善肾功能损伤个体多尿症的方法 | |
| JP3872834B2 (ja) | メイラード反応抑制剤 | |
| WO2000024397A1 (en) | Immunomodulatory drug composition | |
| US6251896B1 (en) | Compositions and methods for the management of Crohn's disease | |
| US20190175511A1 (en) | A Multi-Class Anti-Retroviral Composition | |
| BR112021015088A2 (pt) | Combinações terapêuticas e composições para o tratamento de doença inflamatória intestinal | |
| WO2018192469A1 (en) | Inhibitors of fabp4 and methods of treating arthritis | |
| WO2008069726A1 (en) | Treatment of resistant schizophrenia and other cns disorders by the use of thioxanthenes | |
| WO2000071106A2 (en) | Method of treating weight gain | |
| WO1999051242A1 (fr) | Compositions medicinales pour traiter les oedemes | |
| Nathwani et al. | New Triazole Antifungal Agents (Fluconazole and Itraconazole) in the Treatment of HIV–related Gastrointestinal Candidiasis | |
| Agent | Submission Control No: 156813 | |
| KR970706817A (ko) | 2-[n-(1,2-벤즈이소티아조일-3(2h)온-1,1-디옥사이드] 에틸의 5-에톡시카르보닐-2,4,6-트리메틸-1,4-디히드로피리딘-3-카르복실레이트의 신규한 용도(new applications of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-〔1,2-benzisothiazolyl-3(2h)one-1,1-dioxide〕ethyl |